MediWound (NasdaqGM:MDWD) FY Conference Transcript

Summary of MediWound Conference Call Company Overview - Company: MediWound - Key Products: NexoBrid and EscharEx - Market Focus: Wound care, specifically for severe burns and chronic wounds - Current Financials: $54 million in cash, with a revenue-generating business in NexoBrid Industry Insights - Total Addressable Market (TAM): - Severe burns in the U.S. is approximately $300 million [2] - Chronic wounds applicable to EscharEx are around 4 million, indicating a much larger market potential [5] Product Development and Clinical Trials - NexoBrid: - Approved for eschar removal in severe burns, with a focus on mass casualty events [5][6] - Manufacturing capacity is set to expand sixfold, with inspections by EMA and FDA planned [7][8] - EscharEx: - Undergoing Phase 3 trials for venous leg ulcers (VLUs) and Phase 2 for diabetic foot ulcers (DFUs) [6][9] - Expected to file for approval in 2027, with potential market entry in 2028 [11] Clinical Efficacy - Debridement Efficiency: - EscharEx shows 63% complete debridement within two weeks compared to 0% for SANTYL, a competitor [20] - Average time to wound bed preparation is significantly shorter with EscharEx (48.4 days) compared to SANTYL (76 days) [20] - Market Positioning: - EscharEx aims to capture a significant share of the chronic wound market, with projected peak sales in the U.S. reaching $831 million from a $2.5 billion TAM [20][21] Strategic Partnerships and Funding - Collaborations: - Partnerships with global companies to validate technology and support clinical studies [2][27] - Government Funding: - Initial funding for NexoBrid development has come from U.S. government sources, including the Department of Defense [5] Future Projections - Revenue Growth: - Projected revenue for this year is $24-$26 million, increasing to $32-$35 million next year [11][12] - Potential for higher margins (up to 65%) with increased manufacturing capacity [10] - Market Expansion: - Plans to expand into additional markets, including Europe and Japan, post-approval [8][10] Risks and Considerations - Regulatory Approval: - Success hinges on timely inspections and approvals from EMA and FDA [8][9] - Market Competition: - SANTYL remains a significant competitor, with established market presence and sales of over $370 million annually [18] Conclusion MediWound is positioned for significant growth in the wound care market, with promising clinical data for EscharEx and a solid foundation with NexoBrid. The company is actively expanding its manufacturing capabilities and exploring strategic partnerships to enhance its market presence.